Key facts
- This page summarizes Sanjay Chandru Keswani's Form 4 filing for Annexon, Inc. (ANNX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 15 Feb 2022, 15:37.
Sanjay Chandru Keswani - 11 Feb 2022 Form 4 Insider Report for Annexon, Inc. (ANNX)
- Reporting relationship
- EVP & Chief Medical Officer
- Issuer ticker
- ANNX
- Reported as of
- 11 Feb 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Feb 2022, 15:37:11 UTC
- Next SEC filing
- 04 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Lew, as Attorney-in-Fact for Sanjay Keswani
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sanjay Chandru Keswani filed Form 4 for Annexon, Inc. (ANNX) on 15 Feb 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ANNX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +12,500
- Change %
- Price
- $0.000000
- Shares after
- 12,500
- Date
- 11 Feb 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ANNX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- Price
- $0.000000
- Shares after
- 100,000
- Date
- 11 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $6.94
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 11 of each year, with the first 1/3rd vesting on February 11, 2023.
Footnote F2
Includes 12,500 RSUs.
Footnote F3
1/48th of the shares subject to the option vest on each monthly anniversary measured from February 11, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.